GAMIDA CELL said FDA has granted Breakthrough Therapy Designation to the company’s lead product candidate, NiCord, in development as a novel graft modality for bone marrow transplantation in patients with high risk hematological malignancies. The international, multi-center phase III registration study of NiCord is planned to begin before the end of the year, the company...
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
